Literature DB >> 10702505

CD8(+) T-cell gamma interferon production specific for human immunodeficiency virus type 1 (HIV-1) in HIV-1-infected subjects.

X L Huang1, Z Fan, C Kalinyak, J W Mellors, C R Rinaldo.   

Abstract

The CD8(+)-T-cell response to human immunodeficiency virus type 1 (HIV-1) is considered to be important in host control of infection and prevention of AIDS. We have developed a single-cell enzyme immunoassay (enzyme-linked immunospot assay) specific for gamma interferon (IFN-gamma) production stimulated by either autologous B-lymphoblastoid cell lines (B-LCL) infected with vaccinia virus vectors expressing HIV-1 proteins or synthetic peptides representing known HIV-1 CD8(+) cytotoxic T-lymphocyte (CTL) epitopes. Single-cell IFN-gamma production stimulated by HIV-1 Gag-, Pol-, and Env-expressing B-LCL was a reliable measure of HIV-1-specific T-cell immunity in peripheral blood CD8(+) T cells from HIV-1 infected individuals. This method was more sensitive than stimulation of IFN-gamma by direct infection of the cultures with HIV-1-vaccinia virus vectors. Comparable results were found for IFN-gamma production in CD8(+) T cells from HIV-1-negative, cytomegalovirus (CMV)-seropositive, healthy donors stimulated with B-LCL expressing the CMV pp65 lower matrix protein. HIV-1 peptides were immunodominant for both CD8(+) single-cell IFN-gamma production and CTL precursor frequencies. The number of cells producing IFN-gamma decreased in individuals with late-stage HIV-1 infection and was temporally enhanced during combination antiretroviral therapy with two reverse transcriptase nucleoside inhibitors and a protease inhibitor.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10702505      PMCID: PMC95861          DOI: 10.1128/CDLI.7.2.279-287.2000

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  34 in total

Review 1.  Role of cellular immunity in protection against HIV infection.

Authors:  S Rowland-Jones; R Tan; A McMichael
Journal:  Adv Immunol       Date:  1997       Impact factor: 3.543

2.  Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS.

Authors:  P J Goulder; R E Phillips; R A Colbert; S McAdam; G Ogg; M A Nowak; P Giangrande; G Luzzi; B Morgan; A Edwards; A J McMichael; S Rowland-Jones
Journal:  Nat Med       Date:  1997-02       Impact factor: 53.440

3.  Analysis of the T cell response to tumor and viral peptide antigens by an IFNgamma-ELISPOT assay.

Authors:  C Scheibenbogen; K H Lee; S Stevanovic; M Witzens; M Willhauck; V Waldmann; H Naeher; H G Rammensee; U Keilholz
Journal:  Int J Cancer       Date:  1997-06-11       Impact factor: 7.396

4.  Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load.

Authors:  T Harrer; E Harrer; S A Kalams; P Barbosa; A Trocha; R P Johnson; T Elbeik; M B Feinberg; S P Buchbinder; B D Walker
Journal:  J Immunol       Date:  1996-04-01       Impact factor: 5.422

5.  Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens.

Authors:  W Herr; J Schneider; A W Lohse; K H Meyer zum Büschenfelde; T Wölfel
Journal:  J Immunol Methods       Date:  1996-05-27       Impact factor: 2.303

6.  Detection of human immunodeficiency virus type 1-specific memory cytotoxic T lymphocytes in freshly donated and frozen-thawed peripheral blood mononuclear cells.

Authors:  X L Huang; Z Fan; J Liebmann; C Rinaldo
Journal:  Clin Diagn Lab Immunol       Date:  1995-11

7.  Identification of HIV protein-derived cytotoxic T lymphocyte (CTL) epitopes for their possible use as synthetic vaccine.

Authors:  C Brander; W J Pichler; G Corradin
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

8.  Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection.

Authors:  S M Wolinsky; B T Korber; A U Neumann; M Daniels; K J Kunstman; A J Whetsell; M R Furtado; Y Cao; D D Ho; J T Safrit
Journal:  Science       Date:  1996-04-26       Impact factor: 47.728

9.  Rapid effector function in CD8+ memory T cells.

Authors:  A Lalvani; R Brookes; S Hambleton; W J Britton; A V Hill; A J McMichael
Journal:  J Exp Med       Date:  1997-09-15       Impact factor: 14.307

10.  Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics.

Authors:  M R Klein; C A van Baalen; A M Holwerda; S R Kerkhof Garde; R J Bende; I P Keet; J K Eeftinck-Schattenkerk; A D Osterhaus; H Schuitemaker; F Miedema
Journal:  J Exp Med       Date:  1995-04-01       Impact factor: 14.307

View more
  8 in total

Review 1.  Genomic foundations of evolution and ocular pathogenesis in human adenovirus species D.

Authors:  Ashrafali Mohamed Ismail; Xiaohong Zhou; David W Dyer; Donald Seto; Jaya Rajaiya; James Chodosh
Journal:  FEBS Lett       Date:  2019-12-11       Impact factor: 4.124

2.  Anti-human immunodeficiency virus type 1 (HIV-1) CD8(+) T-lymphocyte reactivity during combination antiretroviral therapy in HIV-1-infected patients with advanced immunodeficiency.

Authors:  C R Rinaldo; X L Huang; Z Fan; J B Margolick; L Borowski; A Hoji; C Kalinyak; D K McMahon; S A Riddler; W H Hildebrand; R B Day; J W Mellors
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

3.  Comprehensive screening for human immunodeficiency virus type 1 subtype-specific CD8 cytotoxic T lymphocytes and definition of degenerate epitopes restricted by HLA-A0207 and -C(W)0304 alleles.

Authors:  Jeffrey R Currier; Mark deSouza; Penprapa Chanbancherd; Wendy Bernstein; Deborah L Birx; Josephine H Cox
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

4.  Restoration of anti-human immunodeficiency virus type 1 (HIV-1) responses in CD8+ T cells from late-stage patients on prolonged antiretroviral therapy by stimulation in vitro with HIV-1 protein-loaded dendritic cells.

Authors:  Z Fan; X L Huang; L Borowski; J W Mellors; C R Rinaldo
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

5.  Safety, tolerability, and immunogenicity of repeated doses of dermavir, a candidate therapeutic HIV vaccine, in HIV-infected patients receiving combination antiretroviral therapy: results of the ACTG 5176 trial.

Authors:  Benigno Rodriguez; David M Asmuth; Roy M Matining; John Spritzler; Jeffrey M Jacobson; Robbie B Mailliard; Xiao-Dong Li; Ana I Martinez; Allan R Tenorio; Franco Lori; Julianna Lisziewicz; Suria Yesmin; Charles R Rinaldo; Richard B Pollard
Journal:  J Acquir Immune Defic Syndr       Date:  2013-12-01       Impact factor: 3.731

6.  Processing and presentation of exogenous HLA class I peptides by dendritic cells from human immunodeficiency virus type 1-infected persons.

Authors:  Xiao-Li Huang; Zheng Fan; Bonnie A Colleton; Rico Buchli; Hongyi Li; William H Hildebrand; Charles R Rinaldo
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

7.  Normal Distribution of CD8+ T-Cell-Derived ELISPOT Counts within Replicates Justifies the Reliance on Parametric Statistics for Identifying Positive Responses.

Authors:  Alexey Y Karulin; Richard Caspell; Marcus Dittrich; Paul V Lehmann
Journal:  Cells       Date:  2015-03-02       Impact factor: 6.600

8.  Positioning of APOBEC3G/F mutational hotspots in the human immunodeficiency virus genome favors reduced recognition by CD8+ T cells.

Authors:  Mahdis Monajemi; Claire F Woodworth; Katrin Zipperlen; Maureen Gallant; Michael D Grant; Mani Larijani
Journal:  PLoS One       Date:  2014-04-10       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.